Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Med Oncol

Search In Journal Title:

Abbravation: Medical Oncology

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1016/0140-6701(95)96402-x

Search In DOI:

ISSN

1559-131X

Search In ISSN:
Search In Title Of Papers:

Attitudes of physicians toward assessing risk and

Authors: Gilles Freyer Ewa KalinkaWarzocha Konstantinos Syrigos Mihai Marinca Giuseppe Tonini Say Liang Ng Zee Wan Wong Antonio Salar Guenther Steger Mahmoud Abdelsalam Lucy DeCosta Zsolt Szabo
Publish Date: 2015/08/28
Volume: 32, Issue: 10, Pages: 236-
PDF Link

Abstract

Febrile neutropenia FN is a potentially fatal complication of chemotherapy This prospective observational study describes physicians’ approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate 10–20  FN risk In the baseline investigator assessment physicians selected factors considered important when assessing overall FN risk and deciding on granulocyte colonystimulating factor GCSF primary prophylaxis PP Physicians then completed patient assessments using the same lists of factors The final FN risk scores and whether GCSF PP was planned were reported The final analysis included 165 physicians and 944 patients The most frequently considered factor in both assessments was chemotherapy agents in the backbone 88  of investigator and 93  of patient assessments History of FN 83  baseline laboratory values 76  and age 73  were commonly selected at baseline whereas tumor type 72  guidelines 62  and tumor stage 43  were selected most during patient assessments Median investigatorreported FN risk threshold for GCSF PP was 20  range 10–85  GCSF PP was planned in 82  of patients with an FN risk at or above this threshold therefore almost onefifth of qualifying patients would not receive GCSF PP Physicians generally follow guidelines but also consider individual patient characteristics when assessing FN risk and deciding on GCSF PP A standardized FN risk assessment may optimize the use of GCSF PP which may minimize the incidence of FN in patients undergoing chemotherapy with an intermediate FN risk ClinicalTrialsgov Identifier NCT01813721This study was sponsored by Amgen We thank all patients physicians coordinators and other staff who participated in the study Medical writing support was provided by Elizabeth Hartfield PhD from Oxford PharmaGenesis Oxford UK Funding for this support was provided by Amgen Europe GmbHGilles Freyer Giuseppe Tonini Konstantinos Syrigos Zee Wan Wong Say Liang Ng and Antonio Salar have declared no conflicts of interest Ewa KalinkaWarzocha has received honoraria from Amgen and Teva Mihai Marinca has received honoraria from Amgen and Sandoz Guenther Steger has received honoraria from and has participated in advisory board meetings for Amgen and Teva Mahmood Abdelsalam has received consultancy fees from Sanofi and honoraria from Eli Lilly and Johnson Johnson He has also received travel grants from Amgen Roche and Astellas and has participated in advisory board meetings for Amgen Janssen and Innomar Strategies Lucy DeCosta and Zsolt Szabo are employees and shareholders of Amgen


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. (Neo-)Adjuvant radiochemotherapy in stage II/III rectal cancer
  2. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia
  3. Understanding venous malformations of the head and neck: a comprehensive insight
  4. Understanding venous malformations of the head and neck: a comprehensive insight
  5. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
  6. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
  7. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy
  8. Lung fluorescence imaging to evaluate tumor metastasis induced by AQP5 expression in murine model
  9. Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?
  10. A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma
  11. Lung cancer in women: histological type and patient age from 1985 to 2005
  12. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer
  13. Primary lymphoma of bone: a case report and review of the literature
  14. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group
  15. Erratum to: Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo
  16. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
  17. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma
  18. Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study
  19. Multiple organ metastases of pulmonary epithelioid haemangioendothelioma and a review of the literature
  20. Association analyses of osteoprotegerin gene polymorphisms with bone mineral density in Chinese postmenopausal women
  21. Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors
  22. Outcomes of locally advanced breast cancer patients with ≥10 positive axillary lymph nodes
  23. Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma
  24. Rap2B promotes cell proliferation, migration and invasion in prostate cancer
  25. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer
  26. Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma
  27. Improved outcome in asymptomatic recurrence following curative surgery for gastric cancer
  28. Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes
  29. Highlights in the adjuvant treatment of colon cancer from annual meetings 2011
  30. Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases
  31. Molecular therapies of colorectal cancer: where will we go from here?
  32. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis
  33. Prognostic significance of epigenetic inactivation of p16 , p15 , MGMT and DAPK genes in follicular lymphoma
  34. The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study
  35. Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature
  36. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival
  37. ASCO 2013: news in early-stage and advanced breast cancer
  38. Salivary biomarkers in cancer detection
  39. CCR7 pathway induces epithelial–mesenchymal transition through up-regulation of Snail signaling in gastric cancer
  40. Tight junction protein claudin-6 inhibits growth and induces the apoptosis of cervical carcinoma cells in vitro and in vivo
  41. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin’s lymphoma and aggressive non-Hodgkin’s lymphoma
  42. Five COX-2 gene polymorphisms and risk of breast cancer: an updated meta-analysis based on 19 case–control studies
  43. Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes
  44. Slug regulates proliferation and invasiveness of esophageal adenocarcinoma cells in vitro and in vivo
  45. Integrating complementary medicine in supportive cancer care models across four continents
  46. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases
  47. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer
  48. ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins
  49. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia
  50. PRRX1 promotes epithelial–mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer
  51. Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis
  52. Neurooncology: current findings and challenges for the future
  53. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma
  54. Intravoxel Incoherent Motion (IVIM) Diffusion Weighted Imaging (DWI) in the Periferic Prostate Cancer Detection and Stratification
  55. High expression of Transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma
  56. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer
  57. miR-200b as a prognostic factor targets multiple members of RAB family in glioma

Search Result: